• Randomized Placebo-Controlled Study of the Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of
  10-Day Monotherapy With BMS-986001, a Novel HIV NRTI, in Treatment-Experienced HIV-1-Infected Subjects.
  Cotte L, Dellamonica P, Raffi F, , et al
  J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):346-354.
  Abstract
• Comparison of supercritical fluid chromatography and reverse phase liquid chromatography for the impurity profiling of the antiretroviral drugs lamivudine/BMS-986001/efavirenz in a combination tablet.
  Alexander AJ, Zhang L, Hooker TF, Tomasella FP.
  J Pharm Biomed Anal. 2013 May 5;78-79:243-51.
  Abstract

BMS-986001